Tissue-Specific Promoters for Factor VIII Expression and Immune Rejection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for conditions like hemophilia A suffer from non-specific gene expression leading to immune rejection and low transduction efficiency, particularly with the B-domain-deleted F8 gene, resulting in low protein secretion and antibody formation.
Innovation Solution
Development of tissue-specific promoters, such as VEC and KDR for endothelial cells, and ITGA and Gp for megakaryocyte-platelet cells, to ensure targeted gene expression in these cell types, reducing immune rejection and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a tissue-specific promoter is used to achieve specific gene expression in target cells, then immune rejection is reduced and transduction efficiency is improved, but the promoter sequence complexity and design difficulty increase
Solution Approach 1:
The patent extracts and isolates specific promoter sequences (VEC, KDR, ITGA, Gp) from complex genomic regions that specifically regulate gene expression in target cells. By taking out only the essential promoter elements needed for tissue-specific expression, the invention achieves reliable specific gene expression while managing sequence complexity through selective extraction of functional elements.
Solution Approach 2:
The patent applies local quality by designing promoters with specific local sequence characteristics that are optimized for expression in particular cell types. Each promoter (VEC for endothelial cells, KDR for endothelial cells, ITGA for megakaryocyte-platelet cells, Gp for megakaryocyte-platelet cells) has unique local sequence features that confer tissue-specific expression, allowing precise control of gene expression in the intended target cells while avoiding expression in unrelated tissues.
2Productivity
If the B-domain-deleted F8 gene is used for gene therapy, then the gene can be delivered via viral vectors, but protein secretion and function remain low and antibody formation occurs
Solution Approach 1:
The patent applies local quality by using tissue-specific promoters to control where and how the F8 gene is expressed. By restricting expression to specific cell types (endothelial cells via VEC/KDR promoters, or megakaryocyte-platelet cells via ITGA/Gp promoters), the invention achieves productive protein secretion in the intended target cells while avoiding ectopic expression that would trigger antibody formation in unrelated tissues.
Solution Approach 2:
The patent uses tissue-specific promoters as intermediaries between the F8 gene and the cellular machinery. These promoters act as mediators that direct gene expression specifically to target cells, enabling productive protein secretion through the appropriate cellular pathways while preventing immune recognition and antibody formation by limiting expression to cells where the protein is naturally produced or tolerated.
Data Source
AI summary
Provided are a tissue-specific promoter and use thereof. The tissue-specific promoter has a nucleic acid sequence comprising more than 80% of the sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The tissue-specific promoter can promote the specific expression of a coding gene in endothelial cells (ECs) or megakaryocyte-platelet cells and can be applied to gene therapy in which a gene is required to be specifically expressed in ECs or megakaryocyte-platelet cells, ensuring a therapeutic effect, reducing a risk of immune rejection and saving a therapeutic cost.